Trial site
Erlanger Medical Center
Chattanooga, Tennessee 37403, United StatesNot linked to an institution yet
- 17running trials
- 9closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 23 trials
- Status
- Active, not recruiting16 trials
- Completed9 trials
- Recruiting1 trial
- Lead sponsor
- National Cancer Institute (NCI)13 trials
- Abbott Medical Devices7 trials
- Boston Scientific Corporation1 trial
- ETOP IBCSG Partners Foundation1 trial
- Javelin Medical1 trial
- and 3 more
Running trials
Recruiting
Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation
NCT05723926· Javelin Medical· Source
Contact: Cleopatra Thurman, Dr
Active, not recruiting
ASCEND CSP IDE Study
NCT06830746· Abbott Medical Devices· Source
Active, not recruiting
Esprit BTK Post-Approval Study
NCT06656364· Abbott Medical Devices· Source
Active, not recruiting
Abbott Atrial Fibrillation Post Approval Study
NCT05434650· Abbott Medical Devices· Source
Active, not recruiting
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755· Medtronic Cardiovascular· Source
Active, not recruiting
CHAMPION-AF Clinical Trial
NCT04394546· Boston Scientific Corporation· Source
Active, not recruiting
Amplatzer Amulet LAAO vs. NOAC
NCT04226547· Abbott Medical Devices· Source
Active, not recruiting
AMPLATZER PFO Occluder Post Approval Study
NCT03309332· Abbott Medical Devices· Source
Active, not recruiting
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
NCT02224781· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01886872· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01575548· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source
Active, not recruiting
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
NCT01274338· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT01134614· Phase 2· National Cancer Institute (NCI)· Source
Active, not recruiting
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT00588770· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
NCT00569127· Phase 3· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error